Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Inovio Pharmaceuticals is COVID-19’s Theranos: Citron

Citron Research is targeting another company. This time it’s Inovio Pharmaceuticals, which the firm compared to Theranos during COVID-19. In a report posted on its website, Citron said that like Theranos, Inovio Pharmaceuticals Inc (NASDAQ:INO) claims to have a “secret sauce” that “supposedly developed a vaccine for COVID-19 in just 3 hours.”

The firm goes on to argue that Inovio investors have been “Theranosed” and that the Securities and Exchange Commission “should immediately halt this blatant stock promotion.”

Inovio Pharmaceuticals reveals algorithm

Citron describes Inovio’s management team as “a group of charlatans.” The firm drew attention to a 60 Minutes interview with Kate Broderick, the company’s SVP of research and development. She said they used a computer algorithm to design a vaccine for COVID-19. After just three hours, she claimed they had “a fully designed vaccine on paper.”

Q1 2020 hedge fund letters, conferences and more

However, this computer algorithm that can supposedly design a COVID-19 vaccine in only three hours isn’t mentioned on any of Inovio Pharmaceuticals’ 10-K or 10-Q filings. Citron said that makes the situation sound like what happened to Theranos.

Stock promotion

The firm went on to describe Inovio Pharmaceuticals as “one of the longest running and most blatant stock promotion schemes” it has ever witnessed.

“The company has a well-documented history of issuing press releases saying they will have the first and best vaccine for whatever infectious disease is in the news headlines during that time,” Citron wrote. “These press releases are followed by highly dilutive stock offerings and large insider sales.”

The firm also pointed to several press releases in which Inovio claimed to have vaccines for other diseases, like the Zika virus. Citron said like with many publicly traded drug makers, Inovio’s stock spikes whenever it releases positive study results, although it generally sees “little if anything of commercial substance arise out of those studies.”

Citron also pointed to a 2009 article that said Inovio Pharmaceuticals has “a habit of issuing fresh shares either to the public or in private placements that often appears synced to its study-result bulletins and stock-price upticks.”

COVID-19 vaccine in the works

Inovio Pharmaceuticals began Phase 1 clinical trials for its COVID-19 vaccine this month. The first phase will determine whether the vaccine is safe, but it doesn’t say anything about whether it’s effective. Based on its track record around other Phase 1 clinical trials for other infectious diseases, Citron expects the company to announce positive data from the Phase 1 trial. However, that expectation doesn’t change its view of the drug maker.

The company issued a press release on March 3 saying that it expects to have 1 million COVID-19 vaccines by the end of this year. However, its FDA filing indicates that the test won’t even be done until next year in a best-case scenario.

“Not a single one of the many promised vaccines has EVER come to market in over 40 years!” Citron wrote. “This is the same platform and same scientific team that has been fleecing investors for decades with promotional press releases and highly dilutive stock offerings.”

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.